Active Ingredient History
Epothilones are a class of potential cancer drugs. Like taxanes, they prevent cancer cells from dividing by interfering with tubulin, but in early trials, epothilones have better efficacy and milder adverse effects than taxanes. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 3)
Carcinoid Tumor (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Central Nervous System Neoplasms (Phase 1)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Glioblastoma (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 1)
Kidney Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1)
Melanoma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neuroendocrine Tumors (Phase 2)
Ovarian Neoplasms (Phase 3)
Peritoneal Neoplasms (Phase 3)
Prostatic Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue